Highlights
- Market Cap
- $35.97M
- Enterprise Value
- $46.48M
- EPS (TTM)
- -$9.32
- Total Revenue (TTM)
- $15.27M
- Gross Profit (TTM)
- $13.87M
- EBITDA (TTM)
- -$58.50M
- Year Range
- $3.00 - $6.95
- ROA (TTM)
- -51.38%
- ROE (TTM)
- -123.87%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Generation Bio Co., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Generation Bio Co.
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.58% | -4.47% | -5.99% | ||||||||||
| 2025 | -26.78% | -25.27% | -30.17% | 6.94% | -12.68% | -15.36% | 38.71% | 35.14% | 2.00% | -9.97% | -3.27% | 6.57% | -46.42% |
| 2024 | 13.94% | 33.51% | 62.15% | -30.47% | 12.37% | -11.32% | 18.44% | -20.96% | -6.44% | -11.74% | -30.28% | -30.26% | -35.76% |
| 2023 | 50.13% | -32.88% | 8.59% | 14.42% | -28.86% | 57.14% | -7.64% | -5.91% | -20.71% | -75.24% | 20.43% | 46.02% | -58.02% |
| 2022 | -8.19% | -21.23% | 43.36% | -13.76% | -11.22% | 16.73% | -2.74% | -19.75% | 3.71% | -3.58% | 4.10% | -26.27% | -44.49% |
| 2021 | -7.13% | 32.62% | -18.50% | 28.11% | -6.03% | -21.48% | -19.18% | 15.00% | 0.28% | -16.39% | -18.08% | -58.77% | -75.03% |
Benchmark Metrics
Generation Bio Co. has an annualized alpha of -36.04%, beta of 1.77, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 15, 2020.
- This stock participated in 248.44% of S&P 500 Index downside but only 46.42% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -36.04%
- Beta
- 1.77
- R²
- 0.09
- Upside Capture
- 46.42%
- Downside Capture
- 248.44%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Generation Bio Co. (GBIO) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Generation Bio Co.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Generation Bio Co. was 99.42%, occurring on Jun 27, 2025. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.42% | Dec 3, 2020 | 1146 | Jun 27, 2025 | — | — | — |
| -31.91% | Sep 3, 2020 | 35 | Oct 22, 2020 | 16 | Nov 13, 2020 | 51 |
| -26.81% | Jun 15, 2020 | 20 | Jul 13, 2020 | 32 | Aug 26, 2020 | 52 |
| -11.32% | Nov 18, 2020 | 2 | Nov 19, 2020 | 3 | Nov 24, 2020 | 5 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Generation Bio Co. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Generation Bio Co. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GBIO relative to other companies in the Biotechnology industry. Currently, GBIO has a P/S ratio of 2.3. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GBIO in comparison with other companies in the Biotechnology industry. Currently, GBIO has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |